LONDON – After more than a decade in clinical development, Pharming Group NV completed the final stage of European approval for its lead product Ruconest, in the treatment of acute attacks of hereditary angioedema (HAE), triggering the payment of a €5 million (US$6.94 million) milestone payment from marketing and distribution partner Swedish Orphan Biomedical AB. (BioWorld International)

With the start of pivotal Phase III clinical trials for eprotirome looming, Karo Bio AB has secured SEK530 million (US$79.7 million) to fund the research, by raising SEK300 million in a forthcoming rights issue that is fully guaranteed and another SEK230 million in an equity-based credit facility. (BioWorld International)

Genmab A/S is banking €7.5 million (US$10.4 million) up front and could earn up to €30.5 million more from a collaboration with H. Lundbeck A/S to develop antibodies against three central nervous system (CNS) targets. (BioWorld International)